Identification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen Receptor
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Transcription activation by androgen receptor (AR), which depends on recruitment of coactivators, is required for the initiation and progression of prostate cancer, yet the mechanisms of how hormone-activated AR interacts with coactivators remain unclear. This is because AR, unlike any other nuclear receptor, prefers its own N-terminal FXXLF motif to the canonical LXXLL motifs of coactivators. Through biochemical and crystallographic studies, we identify that steroid receptor coactivator-3 (SRC3) (also named as amplified in breast cancer-1 or AIB1) interacts strongly with AR via synergistic binding of its first and third LXXLL motifs. Mutagenesis and functional studies confirm that SRC3 is a preferred coactivator for hormone-activated AR. Importantly, AR mutations found in prostate cancer patients correlate with their binding potency to SRC3, corroborating with the emerging role of SRC3 as a prostate cancer oncogene. These results provide a molecular mechanism for the selective utilization of SRC3 by hormone-activated AR, and they link the functional relationship between AR and SRC3 to the development and growth of prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
The coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
Bledsoe, R. K., Montana, V. G., Stanley, T. B., Delves, C. J., Apolito, C. J., McKee, D. D., Consler, T. G., Parks, D. J., Stewart, E. L., Willson, T. M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00817-6 · Cited by 818
Self-citationHeemers, H. V., & Tindall, D. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0019 · Cited by 753
Alen, P., Claessens, F., Verhoeven, G., Rombauts, W., & Peeters, B. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.6085 · Cited by 268
Dubbink, H. J., Hersmus, R., Pike, A. C. W., Molier, M., Brinkmann, A. O., Jenster, G., & Trapman, J. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0348 · Cited by 47
Cited by
Androgen receptor: structure, role in prostate cancer and drug discovery
Tan, M. E., Li, J., Xu, H. E., Melcher, K., & Yong, E.-L. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.18 · Cited by 943
Self-citationAndrogen insensitivity syndrome
Hughes, I. A., Davies, J. D., Bunch, T. I., Pasterski, V., Mastroyannopoulou, K., & MacDougall, J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60071-3 · Cited by 553
Androgen receptor coregulators: recruitment via the coactivator binding groove
van de Wijngaart, D. J., Dubbink, H. J., van Royen, M. E., Trapman, J., & Jenster, G. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.08.007 · Cited by 122
Stelloo, S., Nevedomskaya, E., Kim, Y., Hoekman, L., Bleijerveld, O. B., Mirza, T., Wessels, L. F. A., van Weerden, W. M., Altelaar, A. F. M., Bergman, A. M., et al. (2018) · Oncogene · doi:10.1038/onc.2017.330 · Cited by 118
Axerio-Cilies, P., Lack, N. A., Nayana, M. R. S., Chan, K. H., Yeung, A., Leblanc, E., Guns, E. S. T., Rennie, P. S., & Cherkasov, A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200532b · Cited by 97
Metadata
- Authors
- Zhou, X. E., Suino-Powell, K. M., Li, J., He, Y., MacKeigan, J. P., Melcher, K., Yong, E.-L., & Xu, H. E.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2010-03
- Volume
- 285
- Issue
- 12
- Pages
- 9161-9171
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2126253217
- Cited by
- 106
- References
- 7
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.